166 related articles for article (PubMed ID: 37155014)
1. Sporadic SNCA mutations A18T and A29S exhibit variable effects on protein aggregation, cell viability and oxidative stress.
Joshi N; Sarhadi TR; Raveendran A; Nagotu S
Mol Biol Rep; 2023 Jul; 50(7):5547-5556. PubMed ID: 37155014
[TBL] [Abstract][Full Text] [Related]
2. Role of Sporadic Parkinson Disease Associated Mutations A18T and A29S in Enhanced α-Synuclein Fibrillation and Cytotoxicity.
Kumar S; Jangir DK; Kumar R; Kumari M; Bhavesh NS; Maiti TK
ACS Chem Neurosci; 2018 Feb; 9(2):230-240. PubMed ID: 28841377
[TBL] [Abstract][Full Text] [Related]
3. Novel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson's disease.
Hoffman-Zacharska D; Koziorowski D; Ross OA; Milewski M; Poznanski JA; Jurek M; Wszolek ZK; Soto-Ortolaza A; Awek JAS; Janik P; Jamrozik Z; Potulska-Chromik A; Jasinska-Myga B; Opala G; Krygowska-Wajs A; Czyzewski K; Dickson DW; Bal J; Friedman A
Parkinsonism Relat Disord; 2013 Nov; 19(11):1057-1060. PubMed ID: 23916651
[TBL] [Abstract][Full Text] [Related]
4. Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of α-synuclein.
Rutherford NJ; Moore BD; Golde TE; Giasson BI
J Neurochem; 2014 Dec; 131(6):859-67. PubMed ID: 24984882
[TBL] [Abstract][Full Text] [Related]
5. Effect of endogenous Hsp104 chaperone in yeast models of sporadic and familial Parkinson's disease.
Gade VR; Kardani J; Roy I
Int J Biochem Cell Biol; 2014 Oct; 55():87-92. PubMed ID: 25161148
[TBL] [Abstract][Full Text] [Related]
6. alpha-Synuclein fission yeast model: concentration-dependent aggregation without plasma membrane localization or toxicity.
Brandis KA; Holmes IF; England SJ; Sharma N; Kukreja L; DebBurman SK
J Mol Neurosci; 2006; 28(2):179-91. PubMed ID: 16679557
[TBL] [Abstract][Full Text] [Related]
7. alpha-Synuclein budding yeast model: toxicity enhanced by impaired proteasome and oxidative stress.
Sharma N; Brandis KA; Herrera SK; Johnson BE; Vaidya T; Shrestha R; Debburman SK
J Mol Neurosci; 2006; 28(2):161-78. PubMed ID: 16679556
[TBL] [Abstract][Full Text] [Related]
8. Update on novel familial forms of Parkinson's disease and multiple system atrophy.
Fujioka S; Ogaki K; Tacik PM; Uitti RJ; Ross OA; Wszolek ZK
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1(0 1):S29-34. PubMed ID: 24262183
[TBL] [Abstract][Full Text] [Related]
9. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
[TBL] [Abstract][Full Text] [Related]
10. Absence of Gem1 (mammalian Miro/Rhot) mitigates alpha-synuclein toxicity in a yeast model of Parkinson's disease.
Melo TQ; Palma FR; Gomes F; Netto LES; Ferrari MFR
Mol Cell Neurosci; 2022 Sep; 122():103757. PubMed ID: 35843531
[TBL] [Abstract][Full Text] [Related]
11. Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model.
Gan L; Vargas MR; Johnson DA; Johnson JA
J Neurosci; 2012 Dec; 32(49):17775-87. PubMed ID: 23223297
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.
Fishbein I; Kuo YM; Giasson BI; Nussbaum RL
Brain; 2014 Dec; 137(Pt 12):3235-47. PubMed ID: 25351739
[TBL] [Abstract][Full Text] [Related]
13. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
14. The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease.
Sharma N; Rao SP; Kalivendi SV
Free Radic Biol Med; 2019 May; 135():28-37. PubMed ID: 30796974
[TBL] [Abstract][Full Text] [Related]
15. Tetrahydroxystilbene glucoside inhibits α-synuclein aggregation and apoptosis in A53T α-synuclein-transfected cells exposed to MPP
Zhang R; Sun F; Zhang L; Sun X; Li L
Can J Physiol Pharmacol; 2017 Jun; 95(6):750-758. PubMed ID: 28187263
[TBL] [Abstract][Full Text] [Related]
16. A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
Myöhänen TT; Hannula MJ; Van Elzen R; Gerard M; Van Der Veken P; García-Horsman JA; Baekelandt V; Männistö PT; Lambeir AM
Br J Pharmacol; 2012 Jun; 166(3):1097-113. PubMed ID: 22233220
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Characterization of α-Synuclein Aggregation in Living Cells through Automated Microfluidics Feedback Control.
Perrino G; Wilson C; Santorelli M; di Bernardo D
Cell Rep; 2019 Apr; 27(3):916-927.e5. PubMed ID: 30995486
[TBL] [Abstract][Full Text] [Related]
18. A53T Mutant Alpha-Synuclein Induces Tau-Dependent Postsynaptic Impairment Independently of Neurodegenerative Changes.
Teravskis PJ; Covelo A; Miller EC; Singh B; Martell-Martínez HA; Benneyworth MA; Gallardo C; Oxnard BR; Araque A; Lee MK; Liao D
J Neurosci; 2018 Nov; 38(45):9754-9767. PubMed ID: 30249789
[TBL] [Abstract][Full Text] [Related]
19. Understanding Caffeine's Role in Attenuating the Toxicity of α-Synuclein Aggregates: Implications for Risk of Parkinson's Disease.
Kardani J; Roy I
ACS Chem Neurosci; 2015 Sep; 6(9):1613-25. PubMed ID: 26167732
[TBL] [Abstract][Full Text] [Related]
20. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
